cupure logo
Moderna and Merck's mRNA Cancer Vaccine Shows Promise in Melanoma Trials
Habertürk
Health·

Moderna and Merck's mRNA Cancer Vaccine Shows Promise in Melanoma Trials

Moderna and Merck's personalized mRNA cancer vaccine, Intisomeran, has shown significant success in late-stage clinical trials, notably reducing the risk of melanoma recurrence and spread. Positive results have led to a substantial surge in Moderna's stock value.

Comments

Read this story in other languages

Covered by the press in 5 countries

Among the outlets we follow

  • Türkiye11
  • Germany7
  • United Kingdom3
  • Austria1
  • United States1

Similar News from External Sources

How we write our stories →

DOWNLOAD OUR APP

Cupure iOS App

Cupure writes the day's most important stories in seven languages. The name comes from the French 'coupure de journal' — a newspaper clipping — our promise of concise, relevant news.

For advertising inquiries, content suggestions, or to flag a concern about a news item or content, you can reach us. We value your feedback. Contact form